Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 5
1968 1
1969 3
1970 1
1971 4
1972 1
1973 4
1974 3
1975 6
1976 3
1977 6
1978 5
1979 8
1980 10
1981 6
1982 12
1983 7
1984 13
1985 8
1986 10
1987 9
1988 14
1989 31
1990 25
1991 18
1992 12
1993 21
1994 19
1995 27
1996 24
1997 24
1998 22
1999 41
2000 50
2001 48
2002 40
2003 33
2004 38
2005 34
2006 42
2007 37
2008 25
2009 19
2010 19
2011 11
2012 13
2013 11
2014 9
2015 9
2016 9
2017 3
2018 4
2019 2
2020 8
2021 2
2022 8
2023 7
2024 9
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

856 results

Results by year

Filters applied: . Clear all
Page 1
Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
Donnez J, Becker C, Taylor H, Carmona Herrera F, Donnez O, Horne A, Paszkowski M, Petraglia F, Renner SP, Patel A, Boolell M, Bestel E, Dolmans MM. Donnez J, et al. Hum Reprod. 2024 Jun 3;39(6):1208-1221. doi: 10.1093/humrep/deae076. Hum Reprod. 2024. PMID: 38648863 Free PMC article. Clinical Trial.
STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethindrone acetate, also known as norethisterone acetate [NETA]) demon …
STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add …
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Donnez J, et al. Lancet. 2022 Sep 17;400(10356):896-907. doi: 10.1016/S0140-6736(22)01475-1. Lancet. 2022. PMID: 36116480 Clinical Trial.
Two phase 3 trials were conducted to confirm the efficacy and safety of linzagolix at full-suppression (200 mg) and partial-suppression (100 mg) doses with or without hormonal add-back therapy (1 mg oestradiol and 0.5 mg norethisterone acetate) compared with placebo …
Two phase 3 trials were conducted to confirm the efficacy and safety of linzagolix at full-suppression (200 mg) and partial-suppression (100 …
Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2.
Catherino WH, Al-Hendy A, Zaim S, Bouzegaou N, Venturella R, Stewart EA, Wu R, Vannuccini S, Perry JS, Rakov VG, Munro MG. Catherino WH, et al. Fertil Steril. 2025 Sep;124(3):523-533. doi: 10.1016/j.fertnstert.2025.04.037. Epub 2025 May 2. Fertil Steril. 2025. PMID: 40320117 Free article. Clinical Trial.
INTERVENTION: Once-daily relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg of norethindrone acetate) or placebo for 24 weeks, or delayed relugolix combination therapy (40 mg of relugolix monotherapy for 12 weeks, followed by relugolix combin …
INTERVENTION: Once-daily relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg of norethindrone acetate) …
Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain.
As-Sanie S, Abrao MS, Reznichenko G, Wilk K, Zhong Y, Perry J, Hunsche E, Soulban G, Becker CM. As-Sanie S, et al. Fertil Steril. 2024 Oct;122(4):687-695. doi: 10.1016/j.fertnstert.2024.06.009. Epub 2024 Jun 19. Fertil Steril. 2024. PMID: 38906210 Free article. Clinical Trial.
OBJECTIVE: To evaluate the effect of relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate) for up to 2 years in the SPIRIT long-term extension study on functioning and health-related quality of life (QoL), u …
OBJECTIVE: To evaluate the effect of relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg nore …
Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study.
Donnez J, Petraglia F, Taylor H, Becker CM, Becker S, Herrera FC, Bestel E, Hori S, Dolmans MM. Donnez J, et al. Fertil Steril. 2025 Oct;124(4):737-748. doi: 10.1016/j.fertnstert.2025.06.016. Epub 2025 Jun 19. Fertil Steril. 2025. PMID: 40543832 Free article. Clinical Trial.
OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg with or without hormonal add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethisterone acetate) can maintain the efficacy and …
OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg wi …
Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial.
Miller CE, Kim JH, Kroll R, Simon JA, Soliman AM, Thomas JW, Xu Y, Ng J, Snabes MC. Miller CE, et al. Am J Obstet Gynecol. 2024 Dec;231(6):630.e1-630.e13. doi: 10.1016/j.ajog.2024.06.040. Epub 2024 Jun 30. Am J Obstet Gynecol. 2024. PMID: 38955323 Free article. Clinical Trial.
OBJECTIVE: To evaluate efficacy, tolerability, and bone density outcomes of elagolix 200 mg twice daily with 1 mg estradiol/0.5 mg norethindrone acetate (add-back) therapy once daily compared with placebo in premenopausal women with moderate-to-severe endometriosis- …
OBJECTIVE: To evaluate efficacy, tolerability, and bone density outcomes of elagolix 200 mg twice daily with 1 mg estradiol/0.5 mg …
The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
Moutos D, Smith S, Zacur H. Moutos D, et al. Contraception. 1995 Aug;52(2):105-9. doi: 10.1016/s0010-7824(95)00137-9. Contraception. 1995. PMID: 8536446 Free article. Clinical Trial.
Dehydroepiandrosterone sulfate was suppressed to a similar degree with ethinyl estradiol 35 micrograms/norethindrone 1 mg and ethinyl estradiol 35 micrograms/norethindrone 0.5 mg, but ethinyl estradiol 50 micrograms/norethindrone 1 mg res …
Dehydroepiandrosterone sulfate was suppressed to a similar degree with ethinyl estradiol 35 micrograms/norethindrone 1 mg and …
A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women.
Lukes A, Migoya E, Johnson B, Lee TY, Li Y, Arjona Ferreira JC. Lukes A, et al. Clin Pharmacokinet. 2023 Aug;62(8):1169-1182. doi: 10.1007/s40262-023-01269-9. Epub 2023 Jun 26. Clin Pharmacokinet. 2023. PMID: 37365436 Free PMC article. Clinical Trial.
This study assessed whether the addition of estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg to relugolix 40 mg (relugolix combination therapy) provides systemic E2 concentrations in the 20-50 pg/mL range to minimize these undesirable effects. ...Study as …
This study assessed whether the addition of estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg to relugolix 40 mg (re …
Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial.
Singata-Madliki M, Smit J, Beksinska M, Balakrishna Y, Avenant C, Beesham I, Seocharan I, Batting J, Hapgood JP, Hofmeyr GJ. Singata-Madliki M, et al. PLoS One. 2024 Mar 26;19(3):e0295764. doi: 10.1371/journal.pone.0295764. eCollection 2024. PLoS One. 2024. PMID: 38530848 Free PMC article. Clinical Trial.
BACKGROUND: Observational data suggest lower HIV risk with norethisterone enanthate (NET-EN) than with depo-medroxyprogesterone acetate intramuscular (DMPA-IM) injectable contraceptives. ...We aimed in this paper to investigate the effects of DMPA-IM and NET-EN on estra …
BACKGROUND: Observational data suggest lower HIV risk with norethisterone enanthate (NET-EN) than with depo-medroxyprogesterone aceta …
Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets.
Zdravkovic M, Müller M, Larsen S, Degenkolb J, Pabst G. Zdravkovic M, et al. Int J Clin Pharmacol Ther. 2001 Jan;39(1):41-6. doi: 10.5414/cpp39041. Int J Clin Pharmacol Ther. 2001. PMID: 11204938 Clinical Trial.
OBJECTIVE: The primary objective was to demonstrate bioequivalence between the estrogen components ofActivelle (1 mg estradiol (E2) + 0.5 mg norethisterone acetate (NETA)) and the combined phase of Novofem (1 mg E2 + 1 mg NETA) and between the NETA components of the …
OBJECTIVE: The primary objective was to demonstrate bioequivalence between the estrogen components ofActivelle (1 mg estradiol (E2) + …
856 results